Background: During major ABO-mismatched bone marrow transplant (BMT), the infusion of incompatible red blood cells (RBCs) that are present in the bone marrow graft can cause adverse events from hemolysis. RBC depletion of the bone marrow graft can decrease this risk, but the optimal method to prevent hemolysis is unclear.
INTRODUCTION
ABO incompatibility between donor and recipient in bone marrow transplant (BMT) is common. BMT donors are selected primarily on the basis of the human leukocyte antigen complex that is inherited independent of the ABO blood group system. ABO-incompatible BMTs are characterized as major mismatch when the recipient has anti-A and/or anti-B isohemagglutinins against donor (A→O, B→O, AB→O, AB→A, AB→B), minor mismatch when the donor has isohemaggluAbbreviations: BMT, bone marrow transplant; GFR, glomerular filtration rate; HES, hydroxyethyl starch; RBC, red blood cell tinins against recipient (O→A, O→B, O→AB, A→AB, B→AB), or bidirectional mismatch when both are present (A→B, B→A). The impact of ABO incompatibility on survival after allogeneic hematopoietic stem cell transplantation is controversial with some studies finding no association, [1] [2] [3] [4] [5] [6] [7] [8] and other studies linking ABO incompatibility with increased mortality. [9] [10] [11] [12] [13] [14] [15] Nonetheless, major ABO incompatibility has been consistently associated with increased transfusion requirements and the rare complication pure red blood cell (RBC) aplasia after transplant. [3] [4] [5] 9, 12, 13 Another specific potential complication of major ABO-mismatched BMT is acute hemolysis of incompatible RBCs present in the bone marrow graft. This hemolysis can cause renal dysfunction and, if severe, lead to fatal multiorgan failure. 16, 17 To prevent this infusion complication, two general approaches exist: the BMT recipient's isohemagglutinin titers can be decreased, or the amount of donor RBCs in the bone marrow graft can be decreased. While recipient isohemagglutinin reduction with plasma exchange pre-BMT has been shown to prevent clinically significant infusion-related hemolysis, this approach requires recipients to undergo plasma exchange and can fail to achieve a desired reduction in the isohemagglutinin titer even after multiple exchanges. 18 The alternative approach, graft manipulation to decrease the amount of incompatible RBCs, can be accomplished with various different RBC depletion techniques including hydroxyethyl starch (HES) sedimentation, Ficoll density gradient separation, and blood cell separator processing. [19] [20] [21] [22] [23] Evidence-based guidelines regarding the prevention of major ABOmismatched BMT infusion hemolysis do not exist. Regarding RBC depletion in particular, transplant centers employ different methods and have varied standards with regard to the amount of residual incompatible RBCs that can be infused with the bone marrow graft. 24 This issue is potentially more important in pediatrics, where a small absolute volume of incompatible RBCs could still constitute a significant volume per body weight of the recipient. The Foundation for the Accreditation of Cellular Therapy mandates that institutions should have a "policy for volume of ABO-incompatible red cells in allogeneic cellular therapy products," without mention of a specific volume target. 25 Given this lack of clarity regarding the optimal RBC depletion method, we sought to directly compare hemolysis after major ABO-mismatched BMT infusion between children who underwent RBC depletion with HES sedimentation versus Ficoll density gradient separation. We also sought to characterize the volume of residual incompatible RBCs associated with this hemolysis.
METHODS

Study design
We conducted a retrospective cohort study of all patients who 
Institutional practice for major ABO-mismatched transplants
All major ABO-mismatched BMT patients during this time received similar supportive care with the bone marrow infusion that included premedication with acetaminophen 10-15 mg/kg, diphenhydramine 1 mg/kg, and hydrocortisone 4 mg/kg or methylprednisolone 1-2 mg/kg. All patients received intravenous hyperhydration at 1.5-2 times maintenance starting 4 hr prior to the infusion, continued until two urine tests negative for blood were obtained postinfusion. 
RBC depletion techniques
Isohemagglutinin titers
Patients with a banked pre-BMT plasma sample available for study had IgG isohemagglutinin titers measured using the conventional test tube method. Briefly, 2% suspension of the target RBCs were incubated with each plasma dilution for 1 hr at 37 • C, followed by a 4× wash in saline and subsequent incubation with anti-human globulin IgG. Cells were then centrifuged, followed by examination for agglutination. All testing was performed in parallel using the standard clinical protocols employed by the Emory University Hospital Blood Bank.
Clinical evidence of hemolysis
As a marker of potential hemolysis-induced renal dysfunction, serum creatinine the day after the bone marrow infusion (day +1) was compared to the creatinine the day of the infusion (day 0) to calculate a post/precreatinine ratio. As an additional marker of hemolysis, postinfusion urine dipstick results were available for review on all patients transplanted after 2006. Urine positive for blood was used to define hemoglobinuria.
Statistical analysis
Differences in categorical data were analyzed using the chi-square test or Fisher exact test. Differences in continuous data were analyzed using the Wilcoxon rank-sum test. Statistical calculations were performed with SAS 9.3 (SAS Institute Inc., Cary, NC). Graphics were created using GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA). 
TA B L E 1 Demographic and clinical characteristics of patients
HES (n = 37) Ficoll (n = 16) P-value
RESULTS
Patient characteristics
Fifty-three patients underwent major ABO-mismatched BMT between were similar with the exception that more patients whose grafts underwent RBC depletion with HES had a diagnosis of a malignancy (Table 1) .
Comparison of red blood cell depletion with HES versus Ficoll
The volume of RBCs remaining after RBC depletion with HES was significantly greater than after Ficoll (Table 2 ). Hemoglobinuria after the bone marrow infusion was significantly more common for patients with HES-treated grafts (Table 3) with HES-treated grafts also had a greater than 50% postinfusion rise in their creatinine, but the median creatinine ratios were similar (Table 3) . Only a single patient was noted to have overt renal impairment after the bone marrow infusion requiring changes to the clinical management. This patient received a bone marrow graft that contained 51 ml (1.1 ml/kg) of residual incompatible RBCs after treatment with HES. The details of this patient's clinical course have been previously reported. 16 All patients had donor engraftment with a similar time to neutrophil engraftment for both groups: HES median day +20
versus Ficoll median day +19.5, P = 0.56.
Risk factors for evidence of hemolysis among patients who received HES-treated grafts
Among patients who received HES-treated grafts, patients with hemoglobinuria had a significantly greater increase in their creatinine ratio compared to patients with no hemoglobinuria (median 1.26 vs.
1.00, P = 0.003), and all patients with a greater than 50% creatinine increase had hemoglobinuria. The median volume of incompatible RBCs infused was not significantly different between patients with hemoglobinuria: 24.5 ml (range 4.5-65 ml), 0.74 ml/kg (range 0.23-2.8 ml/kg); and with no hemoglobinuria: 20.5 ml (range 2.7-43 ml), 0.64 ml/kg (range 0.12-1.4 ml/kg) (P = 0.24, 0.63). The total volume of residual RBCs after HES treatment and volume per patient weight was also not significantly associated with the creatinine ratio (Fig. 1) .
Pre-BMT isohemagglutinin titers were measured for nine patients who received HES-treated grafts (Supplementary Table S1 ). All four patients (100%) with an anti-A or anti-B against donor at high titer (≥1:32) had hemoglobinuria, compared to three of five (60%) patients with a low isohemagglutinin titer (≤1:16), P = 0.44. The creatinine ratio was similar for these two groups (high titer 1.14 vs. low titer 1.00, P = 0.99). Pre-BMT glomerular filtration rate (GFR) was not associated with the creatinine ratio when analyzed as a continuous variable ( Supplementary Fig. S1 ) or as a dichotomous variable (abnormal GFR group median ratio 1.0 vs. normal GFR group median ratio 1.0, 
TA B L E 2 Comparison of red blood cell volumes in hydroxyethyl starch versus Ficoll-treated grafts
DISCUSSION
We directly compared for the first time RBC depletion using two different techniques for pediatric major ABO-mismatched BMT. Compared to the HES sedimentation method, RBC depletion with Ficoll density gradient separation achieved smaller residual incompatible RBC volumes and resulted in less evidence of infusion hemolysis.
While bone marrow graft manipulation could affect hematopoietic progenitor cells, we also importantly found that engraftment was similar after these two techniques.
Infusion-related hemolysis was more common with the HES sedi- BMTs. RBC depletion with Ficoll density gradient separation is more labor-intensive for laboratory staff than HES sedimentation, so it may not be chosen by or even possible at many centers. Further research is needed to explore the economics in addition to the safety of RBC depletion methods for major ABO-mismatched BMT.
